Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Published:2023-10-28 Issue:1 Volume:14 Page:169-182
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Rand Kim^ORCID,Ramos-Goñi Juan Manuel^ORCID,Akmaz Bülent,Solé-Feu Laia,Armario-Hita José-Carlos^ORCID

Funder

Almirall

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-01058-z.pdf

Reference42 articles.

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab [Internet]. 2015;66(Suppl. 1):8–16. https://www.karger.com/Article/FullText/370220. Accessed 15 July 2023.

2. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin [Internet]. 2017;35(3):283–9. https://linkinghub.elsevier.com/retrieve/pii/S0733863517300268. Accessed 15 July 2023.

3. Bawany F, Northcott CA, Beck LA, Pigeon WR. Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract [Internet]. 2021;9(4):1488–500. https://linkinghub.elsevier.com/retrieve/pii/S2213219820313398. Accessed 15 July 2023.

4. Maksimović N, Janković S, Marinković J, Sekulović LK, Živković Z, Spirić VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol [Internet]. 2012;39(1):42–7. https://doi.org/10.1111/j.1346-8138.2011.01295.x.

5. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol [Internet]. 2016;74(3):491–8. https://linkinghub.elsevier.com/retrieve/pii/S0190962215024718. Accessed 15 July 2023.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-04

2. Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”;Dermatology and Therapy;2024-03

3. Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’;Dermatology and Therapy;2024-02-16